koo , 

  Your never optimistic always challenging and drawing across the grain ... positive times ahead :))

In other words could market penetration be 50%++ for Apabetalone if there is no other product that competes with Apabetalone ( or little few) to reduce MACE in high risk CVD/type 2DM patient population having a 70% unmet need? 

 Koo 

  Light filters through the darkest rooms , if you open your eyes  Best Wishes !

Stock2740